XENE
Xenon PharmaceuticalsยทNASDAQ
--
--(--)
--
--(--)
XENE Profile
Xenon Pharmaceuticals Inc.
A clinical stage biopharmaceutical company that developing therapeutics for neurological disorders
Biological Technology
11/05/1996
11/05/2014
NASDAQ Stock Exchange
327
12-31
Common stock
200-3650 Gilmore Way, Burnaby, British Columbia V5G 4W8
--
Xenon Pharmaceuticals Inc., was incorporated in British Columbia on November 5, 1996 under the Business Corporations Act (British Columbia) under the name of its predecessor, Xenon Bioresearch Inc. The company is a clinical-stage biopharmaceutical company that discovers and develops a pipeline of differentiated therapies for orphans. The company intends to commercialize itself for a larger market and intends to establish partnerships with global pharmaceutical companies. In order to develop symptomatic drugs, the company has established a core enabling discovery platform by studying rare human diseases with extreme characteristics, including diseases caused by ion channel mutations, also known as ion channel gene mutation diseases. The company has an integrated platform that includes internal functions such as human genetics, small molecule drug discovery and preclinical and clinical development.
